OncoMatch/Clinical Trials/NCT05272696
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
Is NCT05272696 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nab-paclitaxel, cisplatin and Pembrolizumab combination and Radical concurrent chemoradiotherapy for head and neck squamous cell carcinoma.
Treatment: Nab-paclitaxel, cisplatin and Pembrolizumab combination · Radical concurrent chemoradiotherapy — To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC≥1.5×10^9 /L, HGB≥9 g/dL, PLT≥80×10^9 /L
Kidney function
Serum creatinine < 1.5x ULN or CrCl > 60mL/min
Liver function
Total Bilirubin ≤ 1.5 x ULN, AST/ALT ≤ 2.5 x ULN and ALP≤5 x ULN
Cardiac function
No severe heart disease including congestive heart failure, uncontrollable high-risk arrhythmias, unstable angina pectoris, myocardial infarction, and intractable hypertension
Adequate hepatic, cardiac and renal function as demonstrated by 1) Hematology: ANC≥1.5×10^9 /L, HGB≥9 g/dL, PLT≥80×10^9 /L; 2) Renal: Serum creatinine < 1.5x ULN or CrCl > 60mL/min; 3) Hepatic: Total Bilirubin ≤ 1.5 x ULN, AST/ALT ≤ 2.5 x ULN and ALP≤5 x ULN. Patients with severe heart disease include congestive heart failure, uncontrollable high-risk arrhythmias, unstable angina pectoris, myocardial infarction, and intractable hypertension [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify